*Biotechnological production of antigens of Borrelia burgdorferi sensu lato for preparation of prototype of vaccine against Lyme borreliosis.
Project goals
*Research and development of the biotechnological procedure on the level of gene engineering pointed to preparation of protein unites suitable for basic prototype formula of subunit vaccine against Lyme borreliosis.
Keywords
Public support
Provider
Ministry of Industry and Trade
Programme
Project consortia
Call for proposals
Projektová konsorcia 3 (SMPO200300001)
Main participants
Bioveta, a.s.
Contest type
VS - Public tender
Contract ID
—
Alternative language
Project name in Czech
*Biotechnologie výroby antigenů Borrelia burgdorferi sensu lato pro přípravu prototypu vakcíny proti Lymeské borelióze.
Annotation in Czech
*Výzkum a vývoj biotechnologixckých postupů na úrovni genového inženýrství vedoucí k přípravě proteinových jednotek vhodných pro základní prototypovou formuli subjednotkové vakcíny proti Lymeské borelióze.
Scientific branches
R&D category
PV - Industrial research
CEP classification - main branch
EI - Biotechnology and bionics
CEP - secondary branch
FN - Epidemiology, infection diseases and clinical immunology
CEP - another secondary branch
—
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30302 - Epidemiology
30303 - Infectious Diseases
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
Acceptable
Solution timeline
Realization period - beginning
Jan 1, 2003
Realization period - end
Jan 1, 2005
Project status
U - Finished project
Latest support payment
—
Data delivery to CEP
Confidentiality
C - Předmět řešení projektu podléhá obchodnímu tajemství (§ 504 Občanského zákoníku), ale název projektu, cíle projektu a u ukončeného nebo zastaveného projektu zhodnocení výsledku řešení projektu (údaje P03, P04, P15, P19, P29, PN8) dodané do CEP, jsou upraveny tak, aby byly zveřejnitelné.
Data delivery code
CEP06-MPO-FD-U/02:2
Data delivery date
Feb 19, 2007
Finance
Total approved costs
31,871 thou. CZK
Public financial support
11,991 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
19,881 thou. CZK
Basic information
Recognised costs
31 871 CZK thou.
Public support
11 991 CZK thou.
37%
Provider
Ministry of Industry and Trade
CEP
EI - Biotechnology and bionics
Solution period
01. 01. 2003 - 01. 01. 2005